

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vigunia 22313-1450 www.mspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/069,977	03/13/2002	Takakazu Inoue	020159	2998
23850 75	590 09/24/2003	,		
ARMSTRONG,WESTERMAN & HATTORI, LLP 1725 K STREET, NW SUITE 1000			EXAMINER	
			TUNG, JOYCE	
	ON, DC 20006		·	
Wildim (3161), 26 2000			ART UNIT	PAPER NUMBER
			1637	1
			DATE MAILED: 09/24/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 10/069,977 Applicant(s)

Takakazu

Examiner

Joyce Tung

Art Unit **1637**

	The WAILING DATE of this communication appears (on the cover sheet with the correspondence address			
	for Reply	TO EVALUE OF AMONTHUS FROM			
	ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION.	TO EXPIRE3 MONTH(S) FROM			
- Extens	ions of time may be available under the provisions of 37 CFR 1.136 (a). In a	no event, however, may a reply be timely filed after SIX (6) MONTHS from the			
-	g date of this communication. period for reply specified ebove is less than thirty (30) days, a reply within th	ne statutory minimum of thirty (30) days will be considered timely.			
- If NO p		and will expire SIX (6) MONTHS from the mailing date of this communication.			
- Any re	ply received by the Office later than three months after the mailing date of the	• •			
Status	patent term adjustment. See 37 CFR 1.704(b).				
1) 💢	Responsive to communication(s) filed on Jul 10, 20				
2a) 💢	This action is FINAL . 2b) This action	ion is non-final.			
3) 🗆	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.				
Disposi	tion of Claims				
4) 💢	Claim(s) 4-9 and 12-16	is/are pending in the application.			
4	a) Of the above, claim(s)	is/are withdrawn from consideration.			
5) 🗆	Claim(s)	is/are allowed.			
6) 💢	Claim(s) 4-9 and 12-16	is/are rejected.			
7) 🗆	Claim(s)	is/are objected to.			
8) 🗆	Claims	are subject to restriction and/or election requirement.			
Applica	ition Papers				
9) The specification is objected to by the Examiner.					
10)	The drawing(s) filed on is/are	a) \square accepted or b) \square objected to by the Examiner.			
	Applicant may not request that any objection to the de	rawing(s) be held in abeyance. See 37 CFR 1.85(a).			
11)	The proposed drawing correction filed on	is: a) \square approved b) \square disapproved by the Examiner.			
ړ	If approved, corrected drawings are required in reply t	to this Office action.			
12)	The oath or declaration is objected to by the Exami	ner.			
Priority	under 35 U.S.C. §§ 119 and 120				
13)	Acknowledgement is made of a claim for foreign pr	iority under 35 U.S.C. § 119(a)-(d) or (f).			
a) All b) Some* c) None of:					
1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No.					
;	 Copies of the certified copies of the priority do application from the International Burea 	ocuments have been received in this National Stage au (PCT Rule 17.2(a)).			
*S	ee the attached detailed Office action for a list of the	e certified copies not received.			
14)	Acknowledgement is made of a claim for domestic				
	a) The translation of the foreign language provisional application has been received.				
15)	Acknowledgement is made of a claim for domestic	priority under 35 U.S.C. §§ 120 and/or 121.			
Attachm	• •				
1) Notice of References Cited (PTO-892)		4) Interview Summery (PTO-413) Paper No(s).			
Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449) Paper No(s)		5) Notice of Informal Patent Application (PTO-152) 6) Other:			
3,	militation disclosure Statement(s) (PTO-1445) Paper No(s).	6) in Other:			

Art Unit: 1637

DETAILED ACTION

The amendment filed 7/10/2003 has been entered. Following the entry of the amendment, claims 4-9 and 12-16 are pending.

- 1. The rejection of claims 1-14 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-11 of U.S. Patent No.6,287,769 is withdrawn.
- 2. The rejection of claims 1-9 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 11-17 of U.S. Patent No.6274306 is withdrawn.
- 3. The objections of claims 4 and 14 are withdrawn.
- 4. The rejections of claims 10-14 under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention is withdrawn.
- 5. The rejection of claims 1-2 and 9 under 35 U.S.C. 102(b) as being anticipated by Hamad et al. (Journal of Applied Microbiology, 1997, Vol. 83, 764-770) is withdrawn.
- 6. The rejection of claims 10-11 under 35 U.S.C. 102(b) as being anticipated by Wilding et al. (5,498,392) is withdrawn.
- 7. The rejection of claims 3 are rejected under 35 U.S.C. 103(a) as being unpatentable over Hamad et al. (Journal of Applied Microbiology, 1997, Vol. 83, 764-770) as applied to claims 1-2 and 9 above, and further in view of Mullis et al. (4,800,159) is withdrawn.

Application/Control Number: 10/069,977

Art Unit: 1637

8. Claims 4-5, 7-9 and 12-16 are rejected under 35 U.S.C. 103(a) as being unpatentable over Hamad et al. (Journal of Applied Microbiology, 1997, Vol. 83, 764-770), in view of Wilding et al. (5,498,392).

Hamad et al. disclose a method of studying microflora of Sudanese sorghum flour (See pg. 764, the Abstract). Seven strains of *Lactobacillus* were isolated, representing the dominant flora (See pg. 764, the Abstract). The DNA was isolated from lactobacilli (See pg. 765 column 1, five paraph). RAPD-PCR was performed with an arbitrary primer (See pg. 765, column 1, seventh paragraph). The primers used in the method of Hamad have specificity. The agarose electrophoresis patterns were visualized by ethidium bromide staining (See pg. 765, column 2, first paragraph). Hamad et al. also disclose that the partial sequences of the 16S rRNA of all three strains were found to be identical with that of *Lact. vaginalis* (See pg. 766, column 2, last paragraph). The 16S rRNA would have been amplified by using the same primer which amplifies *Lact. vaginalis*. The teachings of Hamad et al. suggest that the primer used which has a sequence capable of amplifying a nucleic acid region coding 16S rRNA of said intestinal bacterium.

Hamad et al. do not disclose using a detector on which said probe are arranged on specific positions in a detector for analyzing an intestinal bacterial flora.

Wilding et al. disclose a device for PCR which includes a detector. The detector has a probe located (See column 4, lines 52-55 and column 11, lines 56-61). Wilding et al. disclose the PCR reaction cycle is complete and then the sample is to be detected (See column 15, lines 11-

16). The detection region includes a labeled polynucleotide probe to detect the amplified polynucleotide (See column 4, lines 45-60).

One of ordinary skill in the art would have been motivated to apply the device of Wilding et al. to the method of Hamad et al. for analyzing the intestinal bacteria flora of a subject. The motivation is that the device of Wilding et al. is for conducting a polynucleotide polymerization reaction to enable the rapid amplification of a polynucleotide in a sample and the device of Wilding et al. includes a detection region which would have been convenient for performing the detection without contamination. It would have been prima_facie obvious to carry out the method of analyzing an intestinal bacterial flora via amplifying the DNA from a subject and hybridizing the amplified DNA with a specific probe positioned on a detector.

The response argues that Hamad et al. do not teach any study on nucleic acid of an intestinal bacterial group in a sample extracted from a subject and Wilding also does not teach this. However, Hamad et al. disclose the study of bacterial flora of Sudanese sorghum flora and the sorghum flour contains the bacterial flora, for example, *Enterococcus faecalis*, (See pg. 764, the Abstract) which is an intestinal bacteria flora. Although Hamad et al. do not disclose the intestinal bacterial flora from a subject, one of ordinary skill would have been motivated to apply the method of Hamad et al. to analyzing the intestinal bacterial flora from a subject because of the teachings of Hamad et al. set forth above that Hamad et al. disclose that the partial sequences of the 16S rRNA of all three strains were found to be identical with that of *Lact. vaginalis* (See pg. 766, column 2, last paragraph). The 16S rRNA would have been amplified by using the same

Art Unit: 1637

primer which amplifies *Lact. vaginalis*. Thus, the teachings of Hamad et al. suggest that the primer used which has a sequence capable of amplifying a nucleic acid region coding 16S rRNA of said intestinal bacteria flora. Wilding disclose a device for amplifying a preselected polynucleotide (See the Abstract).

The response further argues that Wilding et al. and Hamad et al. do not teach rapid simultaneous detection of a plurality of bacteria. However, the method of Hamad et al. was applied to detect a plurality of bacteria since the Sorghum flour contained more than one bacteria (See pg. 765, column 2, third paragraph and pg. 766, column 2, first paragraph and second paragraph). Wilding et al. disclose that the substrate may comprise a plurality of detection/ reaction chambers to enable the rapid parallel detection of polynucleotides in a mixture (See column 5, lines 9-11). Based upon the teachings of Hamad et al. and Wilding et al. one of ordinary skill in the art would have been motivated to apply the device of Wilding et al. in the method of Hamad et al. for analyzing an intestinal bacterial flora of a subject.

Based upon the analysis above, the rejection is maintained.

9. Claim 6 is rejected under 35 U.S.C. 103(a) as being unpatentable over Hamad et al. (Journal of Applied Microbiology, 1997, Vol. 83, 764-770) in view of Wilding et al. (5,498,392) as applied to claims 4-5, 7-9 and 12-16 above, and further in view of Mullis et al. (4,800,159).

The teachings of Hamad et al. and Wilding et al. are set forth in section 8 above.

Hamad et al. do not disclose probes to hybridize to said amplified fragment and that the amplified nucleic acid is used as a probe for detecting an intestinal bacterial flora.

Art Unit: 1637

Mullis et al. disclose a method of polymerase chain reaction for synthesizing the desired nucleic acid sequence and detecting the sequence amplified (See the Abstract). The amplification products were detected by labeled probe (See column 3, lines 16-17).

The teachings of Mullis et al. suggest that the intestinal bacterial flora would have been amplified and detected by hybridizing a nucleic acid probe. The amplified nucleic acid would have been used as probe because the amplified nucleic acid would have the same specificity as the probe used for the detection.

One of ordinary skill in the art at the time of the instant invention would have been motivated to apply the teachings of making the probe used in the method of Mullis et al. to analyze the intestinal bacterial flora of a subject because using probes to hybridizing to an amplified nucleic acid products is more specific for detection. It would have been <u>prima facie</u> obvious to apply the teachings of making probe to detect the amplified nucleic acid sequence of an intestinal bacterial flora in order to analyze the intestinal bacterial flora.

The response argues that the method of Mullis et al. only amplifies a desired single type of DNA fragment and the present invention requires that DNA fragment of a plurality of bacteria are simultaneously amplified and detected by probes arranged on specific positions. Regarding the issue of the plurality of bacteria analyzed and the probes used for the analysis, it has been discussed in section 8 above (See section 8 above). The reference of Mullis et al. provided is for teaching of making the probe which is from the amplified nucleic acid. Based upon the discussion in section 8 above and this section, the rejection is maintained.

Art Unit: 1637

New Grounds of Rejections Necessitated by the Amendments

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

- 12. Claims 12-16 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
- a. Claims 12-16 are vague and indefinite because claims 12-13 depend from the canceled claim 11. In addition, the phrases "the apparatus", "said hybridizer" in claims 12-13, "said nucleic acid amplifier" in claim 14 have no antecedent basis.
- b. Claims 12-16 are vague and indefinite because the language "in which is arranged a probe" is unclear whether the DNA chip has an immobilized probe arranged. Furthermore, regarding the language "having a nucleic acid sequence occurring", it is unclear whether the nucleic acid sequence is comprised by the genome of the intestinal bacterial. Clarification is required.

Art Unit: 1637

Summary

- 13. No claims are allowed.
- 14. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

15. Any inquiries concerning this communication or earlier communications from the examiner should be directed to Joyce Tung whose telephone number is (703) 305-7112. The examiner can normally be reached on Monday-Friday from 8:00 AM-4:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached at (703) 308-1119 on Monday-Friday from 10:00 AM-6:00 PM.

Art Unit: 1637

Any inquiries of a general nature or relating to the status of this application should be directed to the Chemical/Matrix receptionist whose telephone number is (703) 308-0196.

16. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Art Unit 1637 via the PTO Fax Center located in Crystal Mall 1 using (703) 305-3014 or 308-4242. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989).

Joyce Tung

September 11, 2003

Jeffrey SIEW JEFFREY SIEW PRIMARY EXAMINER 9/20/03